150 related articles for article (PubMed ID: 38571280)
1. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.
Nohria A; Desai D; Shapiro J; Bordone L; Lo Sicco K
Int J Dermatol; 2024 Jun; 63(6):e105-e110. PubMed ID: 38571280
[No Abstract] [Full Text] [Related]
2. What's New in Hair Loss.
Santos LDN; Shapiro J
Dermatol Clin; 2019 Apr; 37(2):137-141. PubMed ID: 30850035
[TBL] [Abstract][Full Text] [Related]
3. Scarring Alopecia.
Larrondo J; McMichael AJ
Dermatol Clin; 2023 Jul; 41(3):519-537. PubMed ID: 37236719
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
5. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Melikhov O; Kruglova T; Lytkina K; Melkonyan G; Prokhorovich E; Putsman G; Rodoman G; Vertkin A; Zagrebneva A; Stebbing J
Ann Rheum Dis; 2021 Sep; 80(9):1245-1246. PubMed ID: 34099486
[No Abstract] [Full Text] [Related]
6. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
Chen LC; Ogbutor C; Kelley KJ; Senna MM
J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
[No Abstract] [Full Text] [Related]
7. Primary scarring alopecias.
Rigopoulos D; Stamatios G; Ioannides D
Curr Probl Dermatol; 2015; 47():76-86. PubMed ID: 26370646
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
9. Response to Bhoyrul B., "The treatment of primary cicatricial alopecia is challenging".
Chen LC; Senna MM
J Am Acad Dermatol; 2024 May; 90(5):e185-e186. PubMed ID: 38224915
[No Abstract] [Full Text] [Related]
10. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature.
Sener S; Cam V; Ozen S; Batu ED
Semin Arthritis Rheum; 2024 Jun; 66():152426. PubMed ID: 38442462
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lichen planopilaris with baricitinib: A retrospective study.
Moussa A; Bhoyrul B; Asfour L; Kazmi A; Eisman S; Sinclair RD
J Am Acad Dermatol; 2022 Sep; 87(3):663-666. PubMed ID: 35202778
[No Abstract] [Full Text] [Related]
13. The treatment of primary cicatricial alopecia is challenging.
Bhoyrul B
J Am Acad Dermatol; 2024 May; 90(5):e183-e184. PubMed ID: 38242176
[No Abstract] [Full Text] [Related]
14. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
15. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
Slomski A
JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
[No Abstract] [Full Text] [Related]
16. Cicatricial alopecia as a manifestation of different dermatoses.
Oremović L; Lugović L; Vucić M; Buljan M; Ozanić-Bulić S
Acta Dermatovenerol Croat; 2006; 14(4):246-52. PubMed ID: 17311739
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i27-i33. PubMed ID: 30806706
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
19. Current and future status of JAK inhibitors.
McLornan DP; Pope JE; Gotlib J; Harrison CN
Lancet; 2021 Aug; 398(10302):803-816. PubMed ID: 34454676
[TBL] [Abstract][Full Text] [Related]
20. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
